Nurix Therapeutics, Inc. (NRIX)
2025-05-31 | 2024-08-31 | |||
|---|---|---|---|---|
| Total revenue | 44,056 | 12,588 | ||
| Research and development | 78,096 | 55,481 | ||
| General and administrative | 14,282 | 11,718 | ||
| Total operating expenses | 92,378 | 67,199 | ||
| Loss from operations | -48,322 | -54,611 | ||
| Interest and other income, net | 5,618 | 5,737 | ||
| Loss before income taxes | -42,704 | -48,874 | ||
| Provision for income taxes | 760 | 82 | ||
| Net loss | -43,464 | -48,956 | ||
| Net loss per share, basic (in usd per share) | -0.52 | -0.67 | ||
| Net loss per share, diluted (in usd per share) | -0.52 | -0.67 | ||
| Weighted-average number of shares outstanding, basic (in shares) | 83,882,477 | 72,779,381 | ||
| Weighted-average number of shares outstanding, diluted (in shares) | 83,882,477 | 72,779,381 | ||